

Reducing working capital costs through accelerated release analysis



Infant formula and medical food are subject to strict legislation about their composition, from macronutrients like protein, fat and carbohydrates to micronutrients like vitamins, minerals and trace elements. For young children and people with a medical diet, infant formula or medical food may be their only source of nutrients. Any deficiencies in food composition could lead to serious consequences including disease and growth deviations.

To comply with legislation and avoid any risk to their brand reputation, infant formula and medical food producers carefully monitor the composition not only of their final products, but also the raw materials and intermediates used in the manufacturing process. Typically, analysis and release can take two to three weeks. During this period, large amounts of working capital are tied up in inventory, instead of generating income for the business.

One-week release period

With over 50 years of experience in food analysis, TRISKELION has managed to reduce the release period to just one week. We can offer this accelerated release analysis thanks to our dedicated laboratories for infant formula and medical food which provide analytical services to Europe's leading manufacturers. In these laboratories, our highly skilled technicians perform the relevant tests many times per week with extremely high reliability. We have also streamlined logistics so we get samples from customers quickly. In addition, digital data links with customers have reduced the number of manual steps in the process, ensuring results are delivered promptly.

Significant financial benefits

By releasing working capital faster, accelerated release

analysis can generate significant cost savings. For example, a medium-sized manufacturer of infant formula or medical food produces some 10 million kg of specialized nutrition on an annual basis. With a reduction of the release period to just one week, the manufacturer can release €5.4 million of working capital, corresponding to an annual reduction in capital costs of €270,000. Similarly, a large manufacturer producing 60 million kg of specialized nutrition annually, would release €32 million in working capital and achieve €1.6 million in capital cost reduction per year.

Other analytical service providers have maximized the efficiency of their operations in order to offer testing at the lowest possible cost. However, TRISKELION's accelerated release analysis optimizes working capital so that the resulting savings more than make up for any differences in testing costs.

Discover the capital cost savings for your business with our online calculator.

If you want to release working capital faster through accelerated release analysis, please contact our business development team via **+31 65 000 74 91**.